Glaukos vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Glaukos Corp (GKOS)

Q3 202630 Jul – 9 Oct 2026

▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.
This is the core fundamental driver behind the stock's surge and guidance raise.
Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.
New clinical data validates a key growth product and supports the investment thesis.
iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.
New clinical evidence broadens the addressable market for the flagship product.
Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.
New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.

September 202630 Jul – 9 Oct 2026

▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.
This is the core fundamental driver behind the stock's surge and guidance raise.
Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.
New clinical data validates a key growth product and supports the investment thesis.
iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.
New clinical evidence broadens the addressable market for the flagship product.
Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.
New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.

Latest30 Jul – 9 Oct 2026

▲3

Glaukos Surges on iDose TR and Epioxa Ramp, Raises Guidance

iDose TR and Epioxa drive record revenue and raised guidance Glaukos reported Q2 revenue of $185.6 million, up 50% year over year, with U.S. glaucoma revenue up 64% to $118.5 million and iDose TR sales reaching about $74 million. Management raised 2026 revenue guidance to $680–$700 million, up from $620–$635 million, citing strong adoption of iDose TR and the Epioxa launch. This boosts investor confidence in the growth trajectory.
This is the core fundamental driver behind the stock's surge and guidance raise.
Epioxa shows durable three-year efficacy in keratoconus Glaukos reported positive three-year Phase 3 extension data for Epioxa, showing lasting visual gains and no serious safety issues in keratoconus patients after a single treatment. This supports the corneal health franchise as a second growth pillar alongside glaucoma, potentially expanding the market opportunity and reinforcing long-term revenue prospects.
New clinical data validates a key growth product and supports the investment thesis.
iDose TR plus cataract surgery cuts eye pressure significantly A Phase 4 trial showed iDose TR combined with cataract surgery reduced intraocular pressure by 11.1 mmHg at three months, beating cataract surgery alone by 3.6 mmHg, with a favorable safety profile. This expands the potential use of iDose TR to a large cataract surgery population, opening a new avenue for adoption and revenue growth.
New clinical evidence broadens the addressable market for the flagship product.
Retinal pipeline expansion via RevOpsis license, but stock dipped Glaukos licensed RO-104, a tri-specific biologic for retinal diseases, and gained exclusive rights to the RevMod platform to develop up to four more candidates. While this expands the long-term pipeline, the stock fell 6.3% on the news, possibly due to undisclosed financial terms or investor preference for nearer-term catalysts.
New strategic move with mixed market reaction, relevant to future growth but not immediate revenue.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.